Central Nervous System Disorders Therapeutics Market, by Disease Type (Neurodegenerative Disorders {Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, and Others}, Infectious Diseases, Psychotic Disorders, Anxiety Disorders, Trauma, Mood Disord

Central Nervous System Disorders Therapeutics Market, by Disease Type (Neurodegenerative Disorders {Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, and Others}, Infectious Diseases, Psychotic Disorders, Anxiety Disorders, Trauma, Mood Disorders, and Others), by Drug Class (Analgesics, Anti-cholinergic Agents, Anticonvulsants, Sedatives and Hypnotics, Antidepressants, Antipsychotics, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Central nervous system (CNS) disorders are some of the most prevalent yet poorly treated illnesses. Achieving sufficient blood-brain barrier (BBB) penetration is one of the biggest challenges in the development of therapeutics for CNS disorders. For instance, according to an article published by National Center for Biotechnology Information, in January 2005, more than 98% of small molecular drugs and almost 100% of larger molecular drugs are ineffective in treating CNS diseases considering that BBB strictly limits the delivery of therapeutic agents to their target site in the CNS. BBB helps to keep homeostasis in the cerebral microenvironment by controlling exchanges of substances between the CNS and the blood and serves an important function in preventing macromolecules, infectious substances, and potential neurotoxins from entering the brain. CNS disorders are rising due to factors such as aging, stress, and, lifestyle changes.
A limited understanding of the pathophysiology underlies that most of the psychiatric disorders such as schizophrenia, major depressive disorder, or bipolar disorder are only effective in a limited proportion of the patients. Some of the CNS disorders include neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease along with various infectious diseases, psychiatric disorders, mental disorders, trauma, mood disorders, and others.
Market Dynamics
The key players are focusing on various growth strategies such as collaborations and agreements which is expected to drive the market growth during the forecast period. For instance, in July 2021, Eli Lilly and Company, an American pharmaceutical company and Banner Alzheimer's Institute announced a strategic research collaboration as part of the planned Phase 3, randomized, placebo-controlled study evaluating donanemab, a biological drug in trial to treat early symptoms of Alzheimer's disease in participants at risk for cognitive and functional decline related to Alzheimer's disease (TRAILBLAZER-ALZ 3). TRAILBLAZER-ALZ 3 will evaluate whether treatment with donanemab can slow the clinical progression of Alzheimer's disease in trial participants.
Key features of the study:
This report provides an in-depth analysis of the global central nervous system disorders therapeutics market , and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global central nervous system disorders therapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Biogen Inc., Pfizer Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, AstraZeneca Plc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, AbbVie Inc., Glaxosmithkline plc., Otsuka Pharmaceutical Co., Ltd., Dr. Reddy's Laboratories Ltd., Cipla Inc., Lupin Ltd, and Glenmark Pharmaceuticals
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global central nervous system disorders therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global central nervous system disorders therapeutics market
Detailed Segmentation:
Global central nervous system disorders therapeutics market, By Disease Type:
Neurodegenerative Disorders
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Others
Infectious Diseases
Psychiatric Disorders
Anxiety Disorders
Trauma
Mood Disorders
Others
Global Central Nervous System Disorders Therapeutics Market, By Drug Class:
Analgesics
Anti-cholinergic Agents
Anticonvulsants
Sedatives and Hypnotics
Antidepressants
Antipsychotics
Others
Global Central Nervous System Disorders Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Central Nervous System Disorders Therapeutics Market, By Region:
North America
Disease Type
Neurodegenerative Disorders
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Others
Infectious Diseases
Psychiatric Disorders
Anxiety Disorders
Trauma
Mood Disorders
Others
Drug Class
Analgesics
Anti-cholinergic Agents
Anticonvulsants
Sedatives and Hypnotics
Antidepressants
Antipsychotics
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
Disease Type
Neurodegenerative Disorders
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Others
Infectious Diseases
Psychiatric Disorders
Anxiety Disorders
Trauma
Mood Disorders
Others
Drug Class
Analgesics
Anti-cholinergic Agents
Anticonvulsants
Sedatives and Hypnotics
Antidepressants
Antipsychotics
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Disease Type
Neurodegenerative Disorders
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Others
Infectious Diseases
Psychiatric Disorders
Anxiety Disorders
Trauma
Mood Disorders
Others
Drug Class
Analgesics
Anti-cholinergic Agents
Anticonvulsants
Sedatives and Hypnotics
Antidepressants
Antipsychotics
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Disease Type
Neurodegenerative Disorders
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Others
Infectious Diseases
Psychiatric Disorders
Anxiety Disorders
Trauma
Mood Disorders
Others
Drug Class
Analgesics
Anti-cholinergic Agents
Anticonvulsants
Sedatives and Hypnotics
Antidepressants
Antipsychotics
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Disease Type
Neurodegenerative Disorders
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Others
Infectious Diseases
Psychiatric Disorders
Anxiety Disorders
Trauma
Mood Disorders
Others
Drug Class
Analgesics
Anti-cholinergic Agents
Anticonvulsants
Sedatives and Hypnotics
Antidepressants
Antipsychotics
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
Disease Type
Neurodegenerative Disorders
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Others
Infectious Diseases
Psychiatric Disorders
Anxiety Disorders
Trauma
Mood Disorders
Others
Drug Class
Analgesics
Anti-cholinergic Agents
Anticonvulsants
Sedatives and Hypnotics
Antidepressants
Antipsychotics
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region/Country
South Africa
Central Africa
North Africa
Company Profiles
Biogen Inc.
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Pfizer Inc.
Eli Lilly and Company
Merck & Co., Inc.
Novartis AG
AstraZeneca Plc.
Teva Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
AbbVie Inc.
Glaxosmithkline plc.
Otsuka Pharmaceutical Co., Ltd.
Dr. Reddy's Laboratories Ltd.
Cipla Inc.
Lupin Ltd
Glenmark Pharmaceuticals
“*” marked represents similar segmentation in other categories in the respective section.